Who is sponsoring NCT05288023?

NCT05288023 is sponsored by University of California, San Francisco.

What drugs are being tested in NCT05288023?

Interventions in NCT05288023: Azithromycin for Oral Suspension.

What condition does NCT05288023 study?

NCT05288023 studies Resistance Bacterial, Morality, Child Health, Implementation.

Is NCT05288023 still recruiting?

NCT05288023 is currently terminated. Last updated 28 March 2025.

Are results published for NCT05288023?

Yes — primary outcome results have been posted to ClinicalTrials.gov. See the outcomes section above for details.

Last reviewed 2025-03-28 · How we verify

NCT05288023: AVENIR

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Azithromycin for Child Survival in Niger: Programmatic Trial (AVENIR)

Terminated Phase 4 Results posted Last updated 28 March 2025

What this trial tests

Phase 4 trial testing Azithromycin for Oral Suspension in Resistance Bacterial in 169,707 participants. Terminated before completion.

Timeline

1 December 2022

Primary endpoint
15 January 2024

15 January 2024

Quick facts

Lead sponsor	University of California, San Francisco
Phase	Phase 4
Status	Terminated
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	none
Primary purpose	treatment
Enrollment	169,707
Start date	1 December 2022
Primary completion	15 January 2024
Estimated completion	15 January 2024
Sites	1 location across United States

Drugs / interventions tested

Azithromycin for Oral Suspension — full drug profile →

Conditions studied

Resistance Bacterial — all drugs for Resistance Bacterial →
Morality — all drugs for Morality →
Child Health — all drugs for Child Health →
Implementation — all drugs for Implementation →

Sponsor

University of California, San Francisco

Who can join

1 Month and older, any sex, with Resistance Bacterial or Morality. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The MORDOR trial found that biannual distribution of azithromycin to children 1-59 months old reduced child mortality. The World Health Organization (WHO) released conditional guidelines for this intervention, which include targeting azithromycin distributions to children 1-11 months of age in high mortality settings. The proposed trial aims to demonstrate and evaluate large-scale implementation of azithromycin to children aged 1-11 months old in the context of a programmatic setting while monitoring mortality and resistance antimicrobial resistance.

Publications & conference data

1 peer-reviewed publication reference this trial (live from Europe PMC):

Mass drug administration trials of azithromycin: an analysis to inform future research and guidelines.
Kong AC, So AD. · · 2025 · cited 1× · PMID 40691807 · DOI 10.1186/s40249-025-01322-8

Verify or expand the search:

Other trials of Azithromycin for Oral Suspension

Trials testing the same drug.

NCT06358872 — Azithromycin for Child Survival in Niger II · Phase 4 · recruiting
NCT04774991 — Azithromycin for Child Survival in Niger: Delivery Trial · Phase 4 · completed

Other recruiting trials for Resistance Bacterial

Currently open trials in the same condition.

NCT07514884 — Antimicrobial Stewardship Program Implementation in Brazilian Public Hospitals (PeGASUS) · NA · active not recruiting
NCT04567368 — TB-CAPT MTB/XDR Study · active not recruiting
NCT04188743 — Decolonization of Gram-negative Multi-resistant Organisms (MDRO) with Donor Microbiota (FMT) · Phase 2, PHASE3 · recruiting

Other University of California, San Francisco trials

Trials by the same sponsor.

NCT05284773 — Screening for Acute Malnutrition · NA · withdrawn
NCT04634851 — Video Home Visits for Dietary Counselling · NA · not yet recruiting
NCT06065670 — Assessing Changes in Multi-parametric MRI in Patients With Acute Demyelinating Lesions Taking Clemastine Fumarate as a M · Phase 1, PHASE2 · not yet recruiting
NCT07534098 — Intervention for Hearing Health Among Native Americans · NA · not yet recruiting
NCT06960421 — Exercise-based Frailty Intervention in Lung Transplantation (XFIT) · NA · not yet recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT05288023 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by University of California, San Francisco
Last refreshed: 28 March 2025

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05288023.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing